Sunho Biologics, Inc.

As of December 31, 2024, Sunho Biologics, Inc. has 156.67M shares outstanding.

These figures are as of December 31, 2024.

As of December 31, 2024, Sunho Biologics, Inc. maintains a current ratio of 11.17, meaning it holds 11.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 8.05, indicating elevated leverage, while an interest coverage ratio of -110.29 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2024. Return on assets (ROA) is negative at -18.79, reflecting losses generated across the asset base.

As of the close on April 2, 2026, Sunho Biologics, Inc.'s stock has gained approximately 46.56% over the past 52 weeks. The 50-day moving average sits at 6.44, while the 200-day moving average is 6.86.

These figures cover the twelve months ended December 31, 2024. Total shareholder yield is negative at -73.45, meaning Sunho Biologics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of December 31, 2024, Sunho Biologics, Inc. has an Altman Z-Score of 6.14, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.